Assessment of Hearing Screening Combined With Limited and Expanded Genetic Screening for Newborns in Nantong, China

JAMA Netw Open. 2021 Sep 1;4(9):e2125544. doi: 10.1001/jamanetworkopen.2021.25544.

Abstract

Importance: Early identification and intervention for newborns with hearing loss (HL) may lead to improved physiological and social-emotional outcomes. The current newborn hearing screening is generally beneficial but improvements can be made.

Objective: To assess feasibility and evaluate utility of a modified genetic and hearing screening program for newborn infants.

Design, setting, and participants: This population-based cohort study used a 4-stage genetic and hearing screening program at 6 local hospitals in Nantong city, China. Participants were newborn infants born between January 2016 and June 2020 from the Han population. Statistical analysis was performed from April 1 to May 1, 2021.

Exposures: Limited genetic screening for 15 variants in 4 common HL-associated genes and newborn hearing screening (NHS) were offered concurrently to all newborns. Hearing rescreening and/or diagnostic tests were provided for infants with evidence of HL on NHS or genetic variants on screening. Expanded genetic tests for a broader range of genes were targeted to infants with HL with negative results of limited genetic tests.

Main outcomes and measures: The detection capability for infants with hearing impairment who passed conventional hearing screening, as well as infants with normal hearing at risk of late-onset HL due to genetic susceptibility.

Results: Among a total of 35 930 infants, 32 512 infants completed the follow-up and were included for analysis. Among the infants included in the analysis, all were from the Han population in China and 52.3% (16 988) were male. The modified genetic and hearing screening program revealed 142 cases of HL and 1299 cases of genetic variation. The limited genetic screening helped identify 31 infants who passed newborn hearing screening, reducing time for diagnosis and intervention; 425 infants with normal hearing with pathogenic SLC26A4 variation and 92 infants with MT-RNR1 variation were at risk for enlarged vestibular aqueduct and aminoglycoside-induced ototoxicity respectively, indicating early aversive or preventive management.

Conclusions and relevance: This study found that performing modified genetic and hearing screening in newborns was feasible and provides evidence that the program could identify additional subgroups of infants who need early intervention. These findings suggest an advantage for universal adoption of such a practice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • China
  • Early Diagnosis
  • Feasibility Studies
  • Female
  • Genetic Predisposition to Disease
  • Genetic Testing*
  • Genetic Variation
  • Genotype
  • Hearing Loss / diagnosis*
  • Hearing Loss / genetics
  • Hearing Tests*
  • Humans
  • Infant, Newborn
  • Male
  • Neonatal Screening / methods*
  • Phenotype
  • Pilot Projects
  • Risk Factors